Clinical Scorecard: The Effects of Anxiety and Depression on Outcomes in Hematologic Malignancies: A Systematic Review and Meta-Analysis
At a Glance
Category
Detail
Condition
Hematologic malignancies with comorbid anxiety and depression
Key Mechanisms
Psychological disorders impact survival via decreased treatment adherence, immune system effects, and behavioral pathways
Target Population
Patients diagnosed with hematologic malignancies (e.g., AML, lymphoma, myeloma) with or without anxiety and depression
Care Setting
Oncology and hematology clinical settings managing hematologic malignancies
Key Highlights
Anxiety and depression are prevalent in 20-30% of patients with hematologic malignancies, significantly higher than the general population.
Depression and anxiety are independently associated with reduced overall survival (OS) and event-free survival (EFS) in hematologic malignancies.
Psychological conditions may reduce treatment adherence and impair immune function, contributing to poorer cancer outcomes.
Guideline-Based Recommendations
Diagnosis
Use established clinical criteria (ICD, DSM) or validated scales (HADS, BDI) to diagnose anxiety and depression in patients with hematologic malignancies.
Screen all patients with hematologic malignancies for anxiety and depression due to high prevalence and impact on outcomes.
Management
Integrate psychological support and treatment for anxiety and depression alongside standard hematologic malignancy therapies.
Address behavioral and physiological factors to improve treatment adherence and overall prognosis.
Monitoring & Follow-up
Regularly monitor psychological status during treatment to identify worsening anxiety or depression.
Assess treatment adherence and quality of life as part of comprehensive patient management.
Risks
Unmanaged anxiety and depression increase risk of treatment non-adherence and mortality.
Psychological distress may exacerbate disease progression and reduce survival.
Patient & Prescribing Data
Individuals diagnosed with hematologic malignancies experiencing anxiety and/or depression
Addressing anxiety and depression may improve adherence to chemotherapy and other treatments, potentially enhancing survival outcomes.
Clinical Best Practices
Implement routine screening for anxiety and depression in hematologic malignancy patients using validated tools.
Provide multidisciplinary care including mental health professionals to manage psychological comorbidities.
Educate patients and caregivers about the impact of mental health on cancer outcomes to encourage engagement in psychological care.
Consider both behavioral and inflammatory mechanisms when designing interventions to improve survival.
